ClinicalTrials.gg
RecruitingNCT05263479Updated Apr 3, 2024

A Study of HS-20089 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-20089 (Phase Ia:Dose escalation ) and HS-20089 (Phase Ib: Dose expansion) in Advanced Solid Tumor, sponsored by Shanghai Hansoh Biomedical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Shanghai Hansoh Biomedical Co., Ltd (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
177
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

HS-20089 is a novel DAR-6 antibody-drug conjugate (ADC) targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.

Read the detailed description

This is a Phase 1a/1b open-label, multicenter study with dose escalation and dose expansion cohorts to evaluate the safety, tolerability, PK and preliminary efficacy of HS-20089 in patients with advanced solid tumors.

The Dose Escalation will include an initial accelerated titration design followed by a Bayesian optimal interval (BOIN) design. Enrollment into Dose Expansion will begin after identification of the MTD and/or MAD in Phase 1a. In Phase 1b, preliminary efficacy will be evaluated in planned expansion cohorts that include patients with specific tumor types that are B7-H4+ advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • HS-20089
  • ADC
  • B7-H4
  • Advanced Solid Tumor
03

In context

Lead sponsor

Shanghai Hansoh Biomedical Co., Ltd is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged more than or equal to (≥) 18 years
  2. Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is invalid, unavailable or intolerable
  3. Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required)
  4. performance status was 0-1 and did not deteriorate in the previous 2 weeks
  5. Estimated greater than (>) 12 weeks
  6. Females should be using adequate measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have evidence of non-
  7. Sign Form

Exclusion criteria

Exclusion Criteria:

  1. Treatment with any of the following:

    1. Previous or current treatment with drugs targeting B7-H4
    2. Any cytotoxic chemotherapy, agents or anticancer drugs within 28 days of the first dose of study drug
    3. Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.
    4. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.
    5. Known and untreated, or active central nervous system .
  2. Existing abnormal ≥grade 2 resulted from previous treatment
  3. History of other
  4. Inadequate bone marrow reserve or organ function
  5. Evidence of virus (HBV) or virus (HCV), unless the hepatitis is considered to be cured, Known history of
  6. History of to any active or inactive ingredient of HS-20089.
  7. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  8. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    HS-20089 (Phase Ia:Dose escalation )

    HS-20089 for IV infusion of various dose strengths administered in 21 day dosing cycles.

    Drug: HS-20089 (Phase Ia:Dose escalation )

  • Experimental
    HS-20089 (Phase Ib: Dose expansion)

    The recommended dose from the dose-escalation stage and other potential doses will be further explored.

    Drug: HS-20089 (Phase Ib: Dose expansion)

Interventions

  • Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.

  • IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose of HS-20089

    To determine the MTD for further evaluation of IV administration of HS-20089 in subjects with advanced solid tumors.

    Time frame: 3 weeks after initiation of treatment

Secondary outcomes

  1. Incidence and severity of treatment-emergent adverse events

    The CTCAE criteria will be used to assess adverse events on this trial.

    Time frame: Baseline through study completion(90 days after last dose)

  2. Observed maximum plasma concentration (Cmax) after single dose of HS-20089

    Cmax will be obtained after single dose of HS-20089 on Day 1.

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  3. Observed maximum plasma concentration (Cmax ss) after multiple dose of HS-20089

    Cmax ss will be obtained on Day 1 of dosing in the 21-Day cycle of therapy.

    Time frame: From pre-dose to 24 hours after the dose on Day 1 of the 21-Day cycle of therapy

  4. Apparent terminal half-life (t1/2) after single dose of HS-20089

    Apparent terminal half-life is the time measured for the concentration to decrease by one half.

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  5. Area under plasma concentration versus time curve from zero to the 24-hour sampling time (AUC0-24) after single dose of HS-20089

    Area under the plasma concentration versus time curve from time zero to the 24-hour sampling time at which the concentration was at or above the lower limit of quantification (LLQ).

    Time frame: From pre-dose to 24 hours after single dose on Day 1

  6. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-20089

    Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ).

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  7. Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-20089

    AUC0-∞ was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the LLQ and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: From pre-dose to 120 hours after single dose on Day 1

  8. To further evaluation of the anti-tumor activity of HS-20089 by assessment of objective response rate (ORR)

    Anti-tumor efficacy will be assessed by best radiographic response based on Response Evaluation Criteria in Solid Tumors at baseline (Day -28 to -1). For patients that continue on repeating 21-Day cycles after the primary evaluation period, progression will be assessed after each 6 weeks of therapy. ORR is defined as the percentage of patients with a complete response (CR) or partial response (PR) that was confirmed at a subsequent scan at least 4 weeks later, as assessed according to RECIST version 1.1.

    Time frame: From the date of first occurrence of complete response (CR) or partial response (PR) on 2 consecutive occasions (≥4 weeks), until the date of disease progression or withdrawal from study,up to 2 years

  9. Anti-drug Antibodies (ADA) of HS-20089

    Number of participants who test positive for ADA to HS-20089 will be reported.

    Time frame: Baseline through study completion(90 days after last dose)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Dec 2024, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Mar 2, 2022
StartActual
Jan 5, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2026
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05263479
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Jan 5, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 3, 2024

Study contacts

Jiong Wu, PhD
Contact
wujiong1122@vip.sina.com
13601637369
Jian Zhang, PhD
Contact
Syner2000@163.com
18017312991
Jiong Wu, PhD
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mocertatug rezetecan

Start the discussion